(Q48795479)

English

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

scientific article published on 4 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. (English)

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

phase III clinical trial

0 references

multiple sclerosis

0 references

12

object named as

Ludwig Kappos

1 reference

Europe PubMed Central

15 February 2018

Frederik Barkhof

4

object named as

Frederik Barkhof

1 reference

Europe PubMed Central

15 February 2018

1

object named as

Giancarlo Comi

1 reference

Europe PubMed Central

15 February 2018

Nicola De Stefano

2

object named as

Nicola De Stefano

1 reference

Europe PubMed Central

15 February 2018

author name string

Mark S Freedman

3

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

Chris H Polman

5

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

Bernard M J Uitdehaag

6

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

Florence Casset-Semanaz

7

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

Brian Hennessy

8

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

Margaretha Stam Moraga

9

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

Sanda Rocak

10

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

Bettina Stubinski

11

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

publication date

4 December 2011

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

Lancet Neurology

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

11

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

1

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

33-41

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapses and progression of disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta in multiple sclerosis: how much BENEFIT?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970262-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(11)70262-9

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

1 reference

Europe PubMed Central

15 February 2018

http://europepmc.org/abstract/MED/22146409

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48795479&oldid=1417974876"